2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Roberto Iacovelli, MD, PhD, discusses efficacy findings from the phase 2 ARIES trial in urothelial cancer.
Roberto Iacovelli, MD, PhD, medical oncologist, the Fondazione Policlinico Gemelli IRCCS, Rome, Italy, discusses efficacy findings from the phase 2 ARIES trial (NCT03891238) in urothelial cancer.
The ARIES trial evaluated first-line avelumab (Bavencio) in patients with metastatic and locally advanced urothelial cancer who were PD-L1 positive and unfit for cisplatin-based chemotherapy.
At a median follow-up of 9 months, data from the trial demonstrated a median overall survival (OS) of 10 months in all patients who received avelumab, and the estimated 1-year OS rate was 44.9%, Iacovelli says. Moreover, the median progression-free survival was 2 months.
Notably, avelumab generated an overall response rate of 22.5%. Specifically, 1 patient had a complete response, 21.1% of patients achieved a partial response, and 21.1% of patients had stable disease. These data confirmed the activity of avelumab in this patient population, Iacovelli concludes.